Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Chemotherapy plus durvalumab in triple negative breast cancer

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 04.06.18
Views: 273
Rating:

Prof Sibylle Loibl - German Breast Cancer Group, Frankfurt, Germany

Prof Loibl speaks with ecancer at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting about results from Gepar Nuevo, a trial of anthracycline chemotherapy with durvalumab as a treatment for patients with triple negative breast cancer.

She outlines the patient cohort and stratification for the trial, and the pCR findings which fell just short of statistical significance, though ORR rates were statistically significant, with the best outcomes from patients who were 'primed' with durvalumab.

Prof Loibl also spoke with ecancer about the Gepar X trial, here.

Related videos

follow us

NCRI 2018


Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence